Immuno-oncology
Conference Coverage
Checkmate 214: Upfront nivo/ipi bests TKI in advanced RCC
MADRID – Patients with intermediate- or poor-risk advanced clear-cell RCC treated with nivo/ipi did not reach median OS after 32 months’ follow-up...
News
FDA approves pembrolizumab for gastric and GEJ adenocarcinoma
The checkpoint inhibitor is approved for patients with advanced tumors containing PD-L1 and where the disease is progressing on or after two or...
Conference Coverage
Retrospective review: No difference in PFS, OS with radiation before PD-1/PD-L1 inhibition
CHICAGO – Findings from this small study conflict with some larger studies that showed a significant PFS benefit in lung cancer patients who...
News
FDA approves nivolumab for HCC patients
Approval of nivolumab for HCC was based on tumor response rate and durability of response from the phase 1/2 Checkmate 040 trial.
Conference Coverage
CRP may predict survival after immunotherapy for lung cancer
Median overall survival was more than three times longer for patients with CRP levels at or below 50 mg/L than for those with levels above 50 mg/L...
Conference Coverage
Tocilizumab looks promising for corticosteroid refractory anti-PD-1-related adverse events
CHICAGO – In a review of patients treated with nivolumab, 27 of 34 who were refractory to corticosteroids and treated with tocilizumab for high-...
From the Journals
Adding T-vec might help surmount PD-1 resistance in melanoma
Almost two-thirds of patients with advanced melanoma had at least a partial response and 33% had a complete response to combination therapy with...
From the Journals
Checkmate 238: Nivolumab bests ipilimumab for resectable stage III or IV melanoma
The rates of relapse-free survival were 71% at 12 months for patients assigned to adjuvant nivolumab, compared with 61% for adjuvant ipilimumab....
Conference Coverage
PACIFIC: Durvalumab extends PFS in stage 3 NSCLC
From the Journals
Pembrolizumab, nivolumab linked to 3% rate of neurologic events
Ten of 347 patients (2.9%) receiving nivolumab or pembrolizumab developed subacute neurologic immune-related adverse events, typically...
News
FDA approves first gene therapy – tisagenlecleucel for ALL
“New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to...